These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31974856)

  • 1. Anti-beta-2-glycoprotein I domain 1 identifies antiphospholipid antibodies-related injuries in patients with concomitant lupus nephritis.
    Sciascia S; Radin M; Cecchi I; Fenoglio R; De Marchi A; Besso L; Baldovino S; Rossi D; Miraglia P; Rubini E; Roccatello D
    J Nephrol; 2020 Aug; 33(4):757-762. PubMed ID: 31974856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome.
    Iwaniec T; Kaczor MP; Celińska-Löwenhoff M; Polański S; Musiał J
    Thromb Res; 2017 May; 153():90-94. PubMed ID: 28363116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High IgA antiphospholipid autoantibodies in healthy Sudanese explain the increased prevalence among Sudanese compared to Swedish systemic lupus erythematosus patients.
    Elbagir S; Elshafie AI; Elagib EM; Mohammed NA; Aledrissy MI; Manivel VA; Pertsinidou E; Nur MA; Gunnarsson I; Svenungsson E; Rönnelid J
    Lupus; 2020 Oct; 29(11):1412-1422. PubMed ID: 32741301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2 -glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome.
    Andreoli L; Chighizola CB; Nalli C; Gerosa M; Borghi MO; Pregnolato F; Grossi C; Zanola A; Allegri F; Norman GL; Mahler M; Meroni PL; Tincani A
    Arthritis Rheumatol; 2015 May; 67(8):2196-204. PubMed ID: 25939498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests.
    Day HM; Thiagarajan P; Ahn C; Reveille JD; Tinker KF; Arnett FC
    J Rheumatol; 1998 Apr; 25(4):667-74. PubMed ID: 9558167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta2-glycoprotein I Expression in Lupus Nephritis Patients with Antiphospholipid-associated Nephropathy.
    Gao R; Yu W; Wen Y; Li H
    J Rheumatol; 2016 Nov; 43(11):2026-2032. PubMed ID: 27633824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiphospholipid Antibodies in Lupus Nephritis.
    Parodis I; Arnaud L; Gerhardsson J; Zickert A; Sundelin B; Malmström V; Svenungsson E; Gunnarsson I
    PLoS One; 2016; 11(6):e0158076. PubMed ID: 27336701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies.
    Cabiedes J; Cabral AR; Alarcón-Segovia D
    J Rheumatol; 1995 Oct; 22(10):1899-906. PubMed ID: 8991989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities.
    Sciascia S; Murru V; Sanna G; Roccatello D; Khamashta MA; Bertolaccini ML
    J Thromb Haemost; 2012 Dec; 10(12):2512-8. PubMed ID: 23025466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up.
    Tarr T; Lakos G; Bhattoa HP; Soltesz P; Shoenfeld Y; Szegedi G; Kiss E
    Clin Rev Allergy Immunol; 2007 Apr; 32(2):131-7. PubMed ID: 17916982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus.
    İlgen U; Yayla ME; Ateş A; Okatan İE; Yurteri EU; Torgutalp M; Keleşoğlu ABD; Turgay TM; Kınıklı G
    Lupus; 2018 Apr; 27(4):665-669. PubMed ID: 29050535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients.
    Tarr T; Lakos G; Bhattoa HP; Shoenfeld Y; Szegedi G; Kiss E
    Lupus; 2007; 16(1):39-45. PubMed ID: 17283584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiphospholipid Syndrome and the Kidney.
    Sciascia S; Baldovino S; Schreiber K; Solfietti L; Roccatello D
    Semin Nephrol; 2015 Sep; 35(5):478-86. PubMed ID: 26573550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis.
    Domingues V; Chock EY; Dufrost V; Risse J; Seshan SV; Barbhaiya M; Sartelet H; Erkan D; Wahl D; Zuily S
    Autoimmun Rev; 2022 Oct; 21(10):103158. PubMed ID: 35907609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance and correlations between anti-β2 glycoprotein I IgA assays in antiphospholipid syndrome and/or systemic lupus erythematosus.
    Tebo AE; Willis R; Jaskowski TD; Guerra M; Pierangeli SS; Salmon J; Petri M; Branch DW
    Clin Chim Acta; 2016 Sep; 460():107-13. PubMed ID: 27346478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel enzyme immunoassay system for simultaneous detection of six subclasses of antiphospholipid antibodies for differential diagnosis of antiphospholipid syndrome.
    Nojima J; Motoki Y; Hara K; Sakata T; Ichihara K
    Blood Coagul Fibrinolysis; 2017 Jun; 28(4):316-322. PubMed ID: 27676644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-beta2-glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome.
    von Scheven E; Glidden DV; Elder ME
    Arthritis Rheum; 2002 Aug; 47(4):414-20. PubMed ID: 12209489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.
    Tektonidou MG; Sotsiou F; Nakopoulou L; Vlachoyiannopoulos PG; Moutsopoulos HM
    Arthritis Rheum; 2004 Aug; 50(8):2569-79. PubMed ID: 15334471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiphospholipid antibodies in patients with lupus nephritis: clinical correlations and associations with long-term outcomes.
    Yap DYH; Thong KM; Yung S; Tang C; Ma BMY; Chan TM
    Lupus; 2019 Oct; 28(12):1460-1467. PubMed ID: 31594451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of antibodies to beta2-glycoprotein 1 from patients with systemic lupus erythematosus.
    Cabral AR; Cabiedes J; Alarcón-Segovia D
    Lupus; 2004; 13(3):182-7. PubMed ID: 15119547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.